Abstract
Depression is common in older patients with chronic obstructive pulmonary disease. However, evidence clearly establishing the effectiveness of specific antidepressants in inducing remission of depression and/or improving dyspnoea and physiological measures in this patient population is lacking. Although adherence to pharmacological and rehabilitative treatment is often poor and treatment barriers are multifactorial, collaborative care strategies targeting treatment adherence and behavioural therapy appear to improve depression and dyspnoea-related disability.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yohannes AM, Baldwin RC, Connolly MJ. Mood disorders in patients with chronic obstructive pulmonary disease. Rev Clin Gerontol. 2000;10(2):193–202.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: updated 2014. http://www.goldcopd.com/guidelines-global-strategy-for-diagnosis-management.html. Accessed 15 Sept 2014.
Yohannes AM, Alexopoulos GS. Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes. Drugs Aging. 2014;31(7):483–92.
Atlantis E, Fahey P, Cochrane B, et al. Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest. 2013;144(3):766–77.
Laurin C, Labrecque M, Dupuis G, et al. Chronic obstructive pulmonary disease patients with psychiatric disorders are at greater risk of exacerbations. Psychosom Med. 2009;71(6):667–74.
Ng TP, Niti M, Tan WC, et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167(1):60–7.
Lu Y, Nyunt SZ, Gwee X, et al. Life event stress and chronic obstructive pulmonary disease (COPD): associations with mental well-being and quality of life in a population-based study. BMJ Open. 2012;2:e001674.
Tsai TY, Livneh H, Lu MC, et al. Increased risk and related factors of depression among patients with COPD: a population based cohort study. BMC Public Health. 2013;19(13):976.
Lou P, Chen P, Zhang P, et al. Effects of smoking, depression and anxiety on mortality in COPD patients: a prospective study. Respir Care. 2014;59(1):54–61.
Lu Y, Feng L, Feng L, et al. Systemic inflammation, depression and obstructive pulmonary function: a population-based study. Respir Res. 2013;14:53.
Depression in adults: the treatment and management of depression in adults. NICE clinical guideline 90. London: National Institute for Health and Clinical Excellence; 2009.
Borson S, McDonald GJ, Gayle T, et al. Improvement in mood physical symptoms, and function with nortiptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics. 1992;33(2):190–201.
Gordon GH, Michiels TM, Mahutte CK, et al. Effect of despiramine on control of ventilation and depression scores in patients with chronic obstructive pulmonary disease. Psychiatry Res. 1985;15(1):25–32.
Light RW, Merrill EJ, Despairs J, et al. Doxepin treatment of depressed patients with chronic obstructive pulmonary disease. Arch Intern Med. 1986;146(7):1377–80.
Strom K, Boman G, Pehrsson K, et al. Effect of protriptyline, 10 mg daily, on chronic hypoxemia in chronic obstructive pulmonary disease. Eur Respir J. 1995;8(3):425–9.
Evans M, Hammond M, Wilson K, et al. Placebo-controlled treatment trial of depression in elderly physically ill patients. Int J Geriatr Psychiatry. 1997;12(8):817–24.
Lacasse Y, Beaudoin L, Rousseau L, et al. Randomised trial of paroxetine in end-stage COPD. Monaldi Arch Chest Dis. 2004;61(3):140–7.
Eiser N, Harte R, Spiros K, et al. Effect of treating depression on quality of life and exercise tolerance in severe COPD. COPD. 2005;2(2):233–41.
Shultz E, Malone DA. A practical approach to prescribing antidepressants. Clevl Clin J Med. 2013;80(10):625–31.
Alexopoulos GS, Kiosses DN, Sirey JA, et al. Personalised intervention for people with depression and severe COPD. Br J Psychiatry. 2013;202(3):235–6.
Hynninen MJ, Bjerke N, Pallesen S, et al. A randomized controlled trial of cognitive behavioral therapy for anxiety and depression in COPD. Respir Med. 2010;104(7):986–94.
Kunik ME, Veazey C, Cully JA, et al. COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: a randomized controlled trial. Psychol Med. 2008;38(3):385–96.
Disclosure
This article was adapted from Drugs and Aging 2014;31(7):483–92 [3] by salaried/contracted employees of Adis/Springer, and was not supported by any external funding.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Adis Medical Writers. Consider behavioural strategies in addition to antidepressants in clinically depressed patients with chronic obstructive pulmonary disease. Drugs Ther Perspect 31, 52–56 (2015). https://doi.org/10.1007/s40267-014-0167-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-014-0167-8